Monitor for the actual Form 4 filing to confirm whether the sale was executed. A former officer selling ~$3.8M in stock is a modest signal but not alarming given the small percentage of market cap. No immediate trading action warranted, but watch for additional insider selling patterns in the coming weeks.
TARS drugs
TARS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 19 $73.44entry
- T+1 · 3mo ago −2.63%α −1.79% · $71.51
- T+5 · 3mo ago −3.80%α −3.41% · $70.65
- T+20 · 2mo ago +7.61%α +9.56% · $79.03
- T+60 · 5d ago +4.70%α +6.25% · $76.89
Price Chart
How similar events traded
Executive Summary
Aziz Mottiwala, a former officer of Tarsus Pharmaceuticals, filed a Form 144 notice of intent to sell 53,043 shares of common stock, with an approximate market value of $3.82 million based on the filing date. The shares are being sold through Fidelity Brokerage Services LLC and were acquired via stock option exercise. This is a notable insider sale from a former officer, but as a Form 144 it signals intent to sell, not a completed transaction, and the dollar amount is modest relative to the company's $3.1B market cap (approximately 0.12%).
Key Facts
- Former officer Aziz Mottiwala filed a Form 144 to sell 53,043 shares of Tarsus common stock.
- The approximate market value of the proposed sale is $3,819,096 based on the filing date.
- Shares were acquired via stock option exercise on August 19, 2026.
- The sale is to be executed through Fidelity Brokerage Services LLC.
- The filing represents intent to sell, not a completed transaction.
Financial Impact
Proposed sale of 53,043 shares valued at approximately $3.82 million, representing ~0.12% of TARS's $3.1B market cap.
Risk Factors
- Insider sale may signal reduced conviction from a former officer.
- Form 144 is only an intent to sell; the actual sale may not occur.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-006221 |
| Document: 0001959173-26-006221-index.html | 0001959173-26-006221 |
| Document: 0001959173-26-006221.txt | 0001959173-26-006221 |
Track record
21 reports on TARS
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +27.36% at T+20 after the Aug 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $76.56 Now $78.68 +2.78% settles Nov 23
- Nov 5, 202611d ago 3 Neutral 2/10 Entry $68.60 to $80.28 Now $78.68 +14.69% ▲ +17.03% +14.43% vs SPY
- Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $67.52 to $76.89 Now $78.68 +16.53% ▲ +13.88% +10.59% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $69.07 to $76.76 Now $78.68 +13.91% ▲ +11.13% +12.05% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $69.50 to $70.03 Now $78.68 +13.21% ▲ +0.76% +0.91% vs SPY
- Oct 13, 20264w ago S-3ASR Neutral 4/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
- Oct 13, 20264w ago S-3ASR Neutral 3/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $81.12 to $79.03 Now $78.68 −3.01% ▼ −2.58% −3.21% vs SPY
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $90.78 to $79.95 Now $78.68 −13.33% ▼ −11.93% −10.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers